ANI Pharmaceuticals, Inc. (ANIP) Stock Price
ANIPStock
$72.29−21.38%52W
Market Cap$1.66B
P/E21.20x
PEG Ratio1.74
Div yield—
Beta0.47
ANIP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.57%
Price vs S&P 500 (4W)-6.99%
PEG Ratio1.74
VGM Score67.76
P/E Ratio (Annual)21.20x
ANIP Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.04 | $2.21 | +8.22%(+$0.17) | |
| Q1 2026 | $1.30 | $2.05 | +57.77%(+$0.75) | |
| Q4 2025 | $1.98 | $2.33 | +17.85%(+$0.35) | |
| Q3 2025 | $1.77 | $2.04 | +15.25%(+$0.27) | |
| Q2 2025 | $1.42 | $1.80 | +26.77%(+$0.38) |
ANIP Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.21
4.31
4.21
4.21
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ANIPANI Pharmaceuticals, Inc. | C | A | B | 1.7x | 30.9% | 60.4% | — | $72.29 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals manufactures and markets generic prescription medications, specializing in narcotics, hormones, steroids, and complex formulations including extended-release and combination products. The company operates two business segments—Rare Diseases and Brands, Generics, and Others—with primary operations in the United States and a smaller Canadian presence.